Iqbal Mufti

Iqbal is a Venture Partner based in our London office focused on company creation, later-stage investments and working with portfolio companies on their engagement with industry and their overall partnering strategy and execution.
He is a seasoned pharmaceutical executive with a proven track record in product and portfolio strategy, lifecycle management, late stage development, product launches, global commercialization, affiliate operating leadership, global business development and M&A.
Iqbal recently co-led the rare blood disorders portfolio strategy team at Hoffmann La- Roche where he established the strategy, identified therapeutic focus areas and enabled collaboration across the discovery, development and commercialization teams.
Iqbal was also the global Lifecycle Leader for Hemlibra (emicizumab).
Under his leadership in the 4 years since launch, Hemlibra was approved in over 100 countries and has become one of the largest absolute and relative growth drivers in the Roche portfolio with over USD 3 billion in revenue in 2021.
Iqbal has significant experience in partnering, having worked on many licensing and acquisitions during his tenure at Roche.
He also has operational and commercial experience in multiple territories including the US, Europe and emerging markets.
Education: Iqbal holds a BSc in Biotechnology from University College London and a MBA from Fuqua School of Business, Duke University.